In the phase 2 expansion cohorts, patients with melanoma will receive imneskibart plus aldesleukin (RP2D), with the addition ...
Hundreds more people with an aggressive form of blood cancer can now be offered hope of a cure and “a new lease of life” from today thanks to an NHS drug rollout.
A Stakeholder Interchange convened in Los Angeles, California, by The American Journal of Managed Care explores the treatment ...
In this video, Paolo Strati, MD, discusses the potential of bispecific antibody and antibody-drug conjugate combination therapy for relapsed or refractory diffuse large B-cell lymphoma, based on ...
Expects to Submit Conditional Marketing Approval Application in Europe for Iopofosine I 131 in Refractory (post-BTKi) Waldenstrom’s ...
Paraneoplastic Syndrome, Lung Neoplasia, Electrolyte Imbalance, Geriatric Oncology, Palliative Care Share and Cite: Ramos, F.
The U.S. Food and Drug Administration (FDA) has granted a regenerative medicine advanced therapy designation to MB-105, a CD5 ...
Kura Oncology will host a conference call on November 13, 2025, at 12:30 pm ET / 9:30 am PT – SAN DIEGO and TOYKO, Nov. 13, ...
Two phase 3 trials will study Kura Oncology’s ziftomenib for frontline acute myeloid leukemia, one with venetoclax and the ...
Following the FDA approval of a vagus nerve stimulator for rheumatoid arthritis, supporters of the device’s use have lauded ...
The treatment landscape for systemic lupus erythematosus (SLE) has shifted greatly in recent years, driven by the emergence ...
The U.S. Food and Drug Administration (FDA) has approved Komzifti (ziftomenib), which is a type of treatment known as a menin inhibitor, for use in adults with relapsed or refractory acute myeloid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback